ERBB2 and breast cancer: This also rationalizes the reported sensitivity of early-stage or a metastatic subset of HER2+ BRCA+ patients to targeted therapy by Trastuzumab and provides an alternative means of detecting BC samples harboring BRCA mutations through miRNA signatures [64].